Medical Laboratory Services of Nevada, LLC

Medical Laboratory Services of Nevada, LLC was paid $1.87M by Medicaid between Nov 2022 and Dec 2024, across 41 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 30% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Nevada

Rank by total paid#10 of 31

Median peer was paid$269K

This provider vs. median7.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2022	370	$0.00
2023	12,216	$498K
2024incomplete	33,169	$1.37M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	30%	7,630	5,816	$564K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	20%	12,138	7,198	$374K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	20%	2,198	1,387	$372K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	5.2%	896	271	$97K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.5%	2,904	2,288	$46K
87511		1.9%	1,567	1,153	$36K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.9%	1,565	1,153	$36K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.9%	1,568	1,154	$36K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.9%	1,566	1,153	$36K
87563		1.9%	1,588	1,162	$35K
87640		1.8%	1,483	1,157	$34K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	1.8%	1,459	1,136	$33K

29 more codes

87529		1.4%	626	$26K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	1.4%	466	$26K
87653		1.4%	1,111	$25K
87634		1.0%	468	$19K
87481		<1%	218	$12K
87541		<1%	466	$11K
87581		<1%	466	$11K
87486		<1%	466	$11K
86738		<1%	574	$5K
86780		<1%	573	$5K
86413		<1%	109	$3K
87498		<1%	110	$2K
87532		<1%	109	$2K
87496		<1%	109	$2K
87556		<1%	109	$2K
87503		<1%	109	$1K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	52	$1K
87641		<1%	30	$598.50
87500		<1%	28	$574.56
87590		<1%	29	$342.00
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	13	$333.58
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	14	$247.38
84443	Thyroid stimulating hormone (TSH)	<1%	13	$218.40
80053	Comprehensive metabolic panel	<1%	13	$137.28
85027		<1%	13	$84.11
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	0%	1,309	$0.00
87631		0%	109	$0.00
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	0%	129	$0.00
P9615	Catheterization for collection of specimen(s) (multiple patients)	0%	1,352	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTOM, ANCY (/OWNER/MANAGER)

Same official

Other billing entities under TOM, ANCY

Full network →

Provider	Location	Paid
Psychiatric Associates Professional, LLC	Las Vegas, NV	$577K
Atomkannoth LLC	Las Vegas, NV	$22K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.